What do systematic reviews say?

Aquablation vs transurethral resection of the prostate

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 174 participants
  Low

Aquablation vs transurethral resection of the prostate

It is very uncertain whether aquablation changes major adverse events compared with transurethral resection of the prostate (very low certainty).

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  RR 0.84 [0.31, 2.26]
  1 study · 181 participants
  Very low

Aquablation vs transurethral resection of the prostate

It is very uncertain whether aquablation changes retreatment compared with transurethral resection of the prostate (very low certainty).

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  RR 1.68 [0.18, 15.83]
  1 study · 181 participants
  Very low

Aquablation vs transurethral resection of the prostate

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low

Aquablation vs transurethral resection of the prostate

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Very low

Naftopidil vs tamsulosin

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 965 participants
  Moderate

Naftopidil vs silodosin (alpha‐blocker)

Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.15 [0.06, 0.42]
  4 studies · 348 participants
  Moderate

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Moderate

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Moderate

Naftopidil vs Eviprostat (phytotherapy)

It is very uncertain whether naftopidil changes treatment withdrawals for any reason compared with eviprostat (phytotherapy) (very low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Very low

Naftopidil vs Eviprostat (phytotherapy)

It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Very low

Naftopidil vs tamsulosin

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 878 participants
  Low

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  GRADE not reported

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  GRADE not reported

Naftopidil vs tamsulosin

Naftopidil showed no clear difference in treatment withdrawals for any reason compared with tamsulosin (alpha‐blocker) (low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.92 [0.64, 1.34]
  8 studies · 668 participants
  Low